NewsRelease
Presentationof Stroma Liquid Biopsy at the US Human Proteome Annual Conference
MONMOUTH JUNCTION, NJ, March 28, 2018 -- Biotech Support Group reports on recent research, presented as a poster report and highlighted as a speaker presentation at the 14th Annual US HUPO Conference, held March 11-14, 2018 in Minneapolis, Minnesota USA. This research shows that through robust quantitative mass spectrometry workflows, systemic response to the presence of cancer can be profiled with protein biomarkers. These biomarkers fall within three common pathways which change in the bloodstream regardless of the primary tumor, stage, metastatic disease, or tumor burden. Five different cancers – lung, breast, pancreatic, lymph and ovary, were profiled along with normal/healthy individuals of approximate age and matched sex for comparison.
Thepresentation was entitled “StromaLiquid Biopsy – Pan-Cancer Dysregulation of the SerumProteome”.Itcan be downloaded at:http://www.biotechsupportgroup.com/v/vspfiles/templates/257/pdf/USHUPO2018PosterPrintVersion.pdf
"Afterseveral years of optimizing our AlbuVoid™ bead based enrichmentmethods and aggregating our data, I am very pleased that we canreport what we believe are significant discoveries. Our selection ofbiomarkers offer key advantages as they are all highly observable,being of relative high abundance in the bloodstream. Furthermore,they are all highly differentiated – many severely, in thecancer population, and very stable in the normal/healthy population.Under the guidance of a physician, such dysregulated patterns mayserve within the context of current ‘liquid biopsy’platforms, forming an early indicator for cancer even before clinicalevidence. These same patterns may be prognostic as well as offerindividualized and precision therapy for a patient. We hope to refineour reporting methods with additional investigations in the future.For this, we are engaging partnerships with organizations tocommercialize our proprietary discoveries, so ultimately we canimprove cancer patient outcomes.”, states Dr. Swapan Roy,Ph.D., President and Founder of Biotech Support Group.
Formore information on AlbuVoid™, go to:http://www.biotechsupportgroup.com/AlbuVoid-Albumin-Depletion-and-Low-Abundance-p/avk.htm
AboutBiotech Support Group LLC
Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ forlipid adsorption, HemogloBind™ and HemoVoid™ forhemoglobin removal, and NuGel™ for functional proteomics. Fromthese innovations, the company has acquired knowledgebase andbiomarker intellectual property assets that support discoveries ofprotein markers from blood, with special emphasis on early detectionand personalized medical decisions for cancer patients. For moreinformation, go tohttp://www.biotechsupportgroup.com
Contact:MatthewKuruc 732-274-2866[email protected]